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Kernel Density Estimation was used to examine the lung disease by Age, Length of 
Stay and Total Charges by patient conditions. Text Miner in Enterprise Miner was
used to examine the data according to text strings of treatment procedures. Then we
predict the occurrence of lung cancer according to patient age, gender, days of stay
and total charge with the predictive modeling in Enterprise Miner. RESULTS: There
were 4718 observations related to lung cancer. There are more inpatient events starting 
at age 40, accelerating at age 50 and 55, and decreasing at 65. Patients with lung 
cancer had a higher probability of a stay of ﬁ ve days, which indicates that there was 
a higher probability of higher cost. We deﬁ ned clusters of procedures with a frequency
showing the effectiveness of treatment for patients. The Decision Tree is optimal with
a 22.9% misclassiﬁ cation rate in the testing set compared with other models in Enter-
prise Miner. CONCLUSIONS: Older patients are more likely to have lung cancers 
that would lead to a higher probability of longer stay and higher costs for the treat-
ment procedure. With text analysis on the procedure codes and KDE, it shows that
Levels IV and VI Surgical pathology, gross and microscopic examination are used for 
patients of higher risk with a higher cost compared to other procedures to diagnose
lung cancer.
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OBJECTIVES: Recent changes to ESA prescribing information recommend initiation
at Hb levels  10 g/dL in cancer chemotherapy patients. Real world clinical and eco-
nomic outcomes data associated with this initiation range for the two FDA-approved
ESAs for this population [epoetin alfa (EPO) and darbepoetin alfa (DARB)] are sparse. 
METHODS: Data collected between December 2003 and September 2008 from 61 
U.S. oncology clinics from the Dosing and Outcomes Study of Erythropoietic Stimulat-
ing Therapies (D.O.S.E.) registry were assessed. Patients were included if they were
initiated on ESAs at baseline (BL) Hb  10 g/dL, age   18 years, and received  
2 doses of either EPO or DARB. Outcomes assessed included transfusion utilization, 
cumulative ESA doses, dose ratio (cumulative dose EPO: DARB) and ESA cost (based 
on cumulative ESA dose and December 2008 wholesale acquisition cost: EPO
$13.77/1000 Units, DARB $4.818/mcg). RESULTS: A total of 545 patients (237 EPO, 
308 DARB) were included. BL characteristics were similar between treatment groups
with regard to age, weight, cancer type and Hb. The mean administered dose was
42,610 Units in the EPO group and 259 mcg in the DARB group with a treatment
interval of 11.6 days and 19.4 days, respectively. Mean treatment duration was similar 
between groups (^65 days, P  0.34). The proportion of patients transfused was similar
between groups (^30%, P  0.70). Mean cumulative administered dose was 318,918
Units for EPO and 1,261 mcg for DARB corresponding to a dose ratio of 253:1 (Units 
EPO: mcg DARB). ESA cost was signiﬁ cantly lower in the EPO group compared to
the DARB group (EPO: $4392, DARB: $6075; P  0.001). CONCLUSIONS: In cancer
chemotherapy patients with Hb  10 g/dL prior to ESA initiation, transfusion utiliza-
tion was similar between groups. However, ESA costs were 28% lower in the EPO
group than the DARB group. These ESA-associated outcomes and cost data are 
informative to stakeholders treating cancer chemotherapy patients.
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OBJECTIVES: Myelosuppressive chemotherapy can lead to neutropenia and increase 
infection risk. Myeloid growth factors are commonly used to treat/prevent neutrope-
nia. Sargramostim is a granulocyte-macrophage colony-stimulating factor (GM-CSF).
Unlike ﬁ lgrastim and pegﬁ lgrastim, which are granulocyte colony-stimulating factors 
(G-CSFs), sargramostim activates a broader range of myeloid lineage-derived cells. 
Therefore, GM-CSF might reduce infection risk more than G-CSFs. This study com-
pared real-world infection-related hospitalization rates and costs in patients using
G/GM-CSF for chemotherapy-induced neutropenia. METHODS: This retrospective
matched-cohort study analyzed nationally-representative health insurance claims in 
the US in 2000–2007. The sample population included patients who received chemo-
therapy and G/GM-CSF. G/GM-CSF treatment episodes began with the ﬁ rst adminis-
tration of G/GM-CSF and ended when a subsequent administration was 28 days 
after a prior administration. Sargramostim patients were matched 1:1 with ﬁ lgrastim 
and pegﬁ lgrastim patients based on gender and birth year. Outcomes included infec-
tion-related hospitalization rates and the associated costs. Hospitalization rates were 
analyzed using univariate and multivariate Poisson methods; covariates included
myelosuppressive agents received, tumor type, anemia, and comorbidities. RESULTS:
A total of 990 sargramostim-ﬁ lgrastim and 982 sargramostim-pegﬁ lgrastim pairs were 
analyzed. Cohorts had similar baseline characteristics, though differences were 
observed in the fraction of patients with a neutropenia diagnosis (sargramostim 65%, 
ﬁ lgrastim 57%, pegﬁ lgrastim 45%) and who received myelosuppressive agents (sar-
gramostim 54%, ﬁ lgrastim 48%, pegﬁ lgrastim 77%). Sargramostim patients experi-
enced infection-related hospitalizations about half as often as ﬁ lgrastim (p  0.04) or
pegﬁ lgrastim (p  0.06) patients. Multivariate analyses adjusted for confounding 
factors and found that sargramostim patients were 56% less likely to have infection-
related hospitalizations compared to ﬁ lgrastim and pegﬁ lgrastim patients (p  0.03 
for both). Infection-related hospitalization costs for sargramostim patients were $728/
patient/month and $226/patient/month less compared to ﬁ lgrastim (p  0.04) and 
pegﬁ lgrastim patients (p  0.01), respectively. CONCLUSIONS: Among patients with
chemotherapy-induced neutropenia, sargramostim use is associated with reduced risk 
of infection-related hospitalization and lower associated costs compared to ﬁ lgrastim
or pegﬁ lgrastim.
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OBJECTIVES: Breast cancer prevention and control in low-and middle-income coun-
tries (LMCs) are critical emerging issues. Most LMCs lack sufﬁ cient resources for
screening, early detection, and treatment of breast cancer. However, little is known 
about what works to reduce the burden of breast cancer in low-resource settings or
how best to maximize public health interventions. The purpose of this study was to
assemble a knowledge base of studies in LMCs on breast cancer prevention, early 
detection, treatment, and palliative care that address issues of equity, access, and costs. 
METHODS: We conducted a systematic literature search via PUBMED and other 
computerized electronic databases. We classiﬁ ed each citation as relevant, peripherally 
relevant, not relevant, or unknown and maximized the criteria by using free-text words
and medical subject headings. All citations identiﬁ ed were independently reviewed by 
three members of the research team. Relevant studies were selected if they met inclu-
sion criteria: published in English or Spanish between January 1, 1990 and April 30,
2008. RESULTS: A total of 1907 citations were identiﬁ ed, of which, 53.2% were
excluded as “not relevant;” 27.1% were considered likely to be “relevant”; 5.5% were 
coded “peripherally relevant”; and 6.0% were “unknown”. All relevant articles (516) 
coming from 60 LMCs met the inclusion criteria and were abstracted. We found 80 
articles on East Asia/Paciﬁ c countries; 82 on Europe/Central Asia countries; 76 on
Latin American/Caribbean countries; 64 on Middle East/North Africa countries; 100
on South Asia countries; 71 on Sub-Saharan Africa countries; and 43 articles with no
region-speciﬁ c focus. We identiﬁ ed three articles on palliation and end-of-life care and 
a small number of articles reported cost data or economic analyses. CONCLUSIONS:
The review contains a wealth of practical information that would be extremely useful
to the myriad of clinicians and public health professionals working to prevent and 
treat breast cancer in LMCs.
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OBJECTIVES: Worldwide, the association of passive smoking with development of 
lung cancer has been ascertained. However, it remains unknown of the magnitude of 
the association in the Chinese population. We thus systematically reviewed the pub-
lished studies worldwide. METHODS: We searched Medline, EMBASE, and three 
other Chinese databases from their inception to June 30, 2008. We included case-
control and cohort studies that investigated the association of passive smoking with 
lung cancer, and that provided data on the magnitude of the association. Two reviewers 
screened the eligibility, assessed the extent of the bias, and extracted data independently.
We obtained the unadjusted and adjusted estimates of studies. We pooled the trial data 
using the random-effect model and explored the heterogeneity by the pre-speciﬁ ed 
variables. RESULTS: We included 20 studies (n  88,379). One was cohort study (n 
72,829) and 19 case-control studies (cumulative cases: 5977, and controls: 9573). 
Passive smoking increase the risk of lung cancer by 25% (OR  1.25, 95%CI  1.03 
to 1.47). Pooling of adjusted estimates of 10 case-control studies (2704 cases and 3495
controls) showed that the risk of lung cancer increased by 95% (1.95, 1.49 to 2.55).
In female life-long non-smokers, the passive smoking increased the risk of lung cancer
by 77% (1.77, 1.22 to 2.58, n  5685), and increased the risk of squamous cell carci-
noma and adenocarcinoma of female non-smokers by 99% (1.99, 1.19 to 3.33) and 
7% (1.05, 0.45 to 2.51). Because of the limited data, no signiﬁ cant dose-response
relationship was found between the risk of lung cancer and the exposure amounts,
durations and the initiating age. CONCLUSIONS: The increased risk of lung cancer 
associated with passive smoking in the Chinese population has been ascertained.
Passive smoking has a strong association with squamous cell carcinoma.
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OBJECTIVES: Worldwide, the association of smoking with development of lung 
cancer has been ascertained. However, it remains unknown of the magnitude of the 
association in the Chinese population. We thus systematically reviewed the published 
